Symbiotec Pharmalab Limited announced robust financial results for the second quarter and half year ended September 30, 2026. The company reported a 43% increase in consolidated revenues and a substantial 169% surge in consolidated PAT for Q2 FY27 compared to the previous year. The API business also showed steady growth with a 16% rise in operating revenue.
Symbiotec Pharmalab Delivers Strong Financial Performance
Symbiotec Pharmalab Limited, a global leader in corticosteroid and steroidal-hormone APIs, has announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company showcased a significant performance, with consolidated revenues growing by 43% and consolidated Profit After Tax (PAT) soaring by 169% on a year-on-year basis for Q2 FY27.
Key Financial Highlights
The consolidated revenues for Q2 FY27 reached ₹280 crore, up from ₹196 crore in Q2 FY26. Consolidated PAT for the quarter was ₹52 crore, a substantial increase from ₹19 crore in the same period last year. The company also noted that these results exclude a one-time IPO expense of approximately ₹3 crore.
For the half-year ended September 30, 2026, consolidated revenues grew by 25% to ₹498 crore, while consolidated PAT saw a 34% increase to ₹66 crore.
API Business Performance
The core API business demonstrated healthy growth, with operating revenues increasing by 16% to ₹227 crore in Q2 FY27. EBIDTA for the API segment rose by 21% to ₹71 crore. The company highlighted that API gross margins remain above 60%, and API EBIDTA margins are steady at approximately 30%, driven by revenue growth and a favourable sales mix.
Operational Achievements and Future Outlook
Symbiotec Pharmalab also detailed several key operational highlights. The company successfully completed four major regulatory audits in March 2026 and H1 FY27, receiving approval certifications and EIRs for its Rau and Pithampur plants. In the Complex Injectables segment, a licensing agreement for the distribution of two DCV products in the US was signed, with milestone-based revenues of ₹53 crore recognized in Q2 FY27.
The company is also progressing with filings for new DCV products, including the first generic filing in the US market and the submission of a pre-submission facility correspondence for expedited priority review.
Furthermore, Symbiotec is expanding its CDMO services, with a 10-year take-or-pay agreement with a European player in the alternative protein space at an advanced stage. The company has invested approximately ₹1,672 crore in capex by the end of FY27, with 61% allocated to new revenue-generating businesses. Net debt stood at approximately ₹314 crore as of September 30, 2026.
Mr. Anil Satwani, Chairman & Managing Director, expressed confidence in the company’s growth outlook, stating, “We believe our Injectables and CDMO businesses have the potential to scale meaningfully over the coming years and ultimately reach a size comparable to our established API business.”
Source: BSE
